224 related articles for article (PubMed ID: 32172728)
21. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
22. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase.
Adelsman MA; McCarthy JB; Shimizu Y
Mol Biol Cell; 1999 Sep; 10(9):2861-78. PubMed ID: 10473632
[TBL] [Abstract][Full Text] [Related]
23. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
[TBL] [Abstract][Full Text] [Related]
24. Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia.
Liu Z; Carvajal M; Carraway CA; Carraway K; Pflugfelder SC
Cornea; 2001 Jan; 20(1):81-5. PubMed ID: 11189010
[TBL] [Abstract][Full Text] [Related]
25. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Wang DD; Ma L; Wong MP; Lee VH; Yan H
PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617
[TBL] [Abstract][Full Text] [Related]
26. The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner.
Sak MM; Breen K; Rønning SB; Pedersen NM; Bertelsen V; Stang E; Madshus IH
Carcinogenesis; 2012 May; 33(5):1031-9. PubMed ID: 22436610
[TBL] [Abstract][Full Text] [Related]
27. Review on EGFR Inhibitors: Critical Updates.
Singh D; Attri BK; Gill RK; Bariwal J
Mini Rev Med Chem; 2016; 16(14):1134-66. PubMed ID: 26996617
[TBL] [Abstract][Full Text] [Related]
28. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
Carrasco-García E; Saceda M; Grasso S; Rocamora-Reverte L; Conde M; Gómez-Martínez A; García-Morales P; Ferragut JA; Martínez-Lacaci I
Exp Cell Res; 2011 Jun; 317(10):1476-89. PubMed ID: 21439954
[TBL] [Abstract][Full Text] [Related]
29. The expression and prognostic value of the epidermal growth factor receptor family in glioma.
Xu B; Huo Z; Huang H; Ji W; Bian Z; Jiao J; Sun J; Shao J
BMC Cancer; 2021 Apr; 21(1):451. PubMed ID: 33892666
[TBL] [Abstract][Full Text] [Related]
30. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
31. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
32. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
33. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Zhang X; Belkina N; Jacob HK; Maity T; Biswas R; Venugopalan A; Shaw PG; Kim MS; Chaerkady R; Pandey A; Guha U
Proteomics; 2015 Jan; 15(2-3):340-55. PubMed ID: 25404012
[TBL] [Abstract][Full Text] [Related]
34. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
35. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
36. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
37. Myofibroblasts have an impact on expression, dimerization and signaling of different ErbB receptors in OSCC cells.
Büttner R; Berndt A; Valkova C; Richter P; Korn A; Kosan C; Liebmann C
J Recept Signal Transduct Res; 2017 Feb; 37(1):25-37. PubMed ID: 27051967
[TBL] [Abstract][Full Text] [Related]
38. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2.
Maurer CA; Friess H; Kretschmann B; Zimmermann A; Stauffer A; Baer HU; Korc M; Büchler MW
Hum Pathol; 1998 Aug; 29(8):771-7. PubMed ID: 9712416
[TBL] [Abstract][Full Text] [Related]
40. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
Wang X; Xu L; Lao Y; Zhang H; Xu H
Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
